Ramses, I agree about the run. It ran on some very strong evidence that PBT2 can do the impossible and repair Alzheimers damaged neurons and their connections. It revealed a mechanism of action to explain the cognition gains seen in the human trial.
That capability has not gone away and there has been other independent research on the restoration of synaptic function by PBT2, also how PBT2 protects against the final stage of cell death(also applicable to Huntingtons) and here we are at the exact same value as before the run.
Prana really need to go to the next step and get a trial started. Which is what they are doing.
eli lilley alz success could double market cap, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $16.27K | 5.423M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 82 | 102014005 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 604830 | 2 |
View Market Depth
| Last trade - 14.09pm 13/11/2024 (20 minute delay) ? |
| ATH (ASX) Chart |